Category Archives: Other

BI Creates Metabolic Health Steering Committee; Reta Tops Ozempic; Lilly Initiates Elora CV Safety Study; Dexcom to Launch G7 15 Day in Canada; Viking and Beta Bionics Q3 ’26 Earnings

A series of cardiometabolic-related news items has been observed from Boehringer Ingelheim, Lilly, Viking, Dexcom, and Beta Bionics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novartis and Wave Q3 ’26 Earnings; Hengrui Business Updates; Novo/Lilly DTC Ad Lawsuit; EVP and President of Lilly International to Retire

A series of cardiometabolic-related news items has been observed from Novartis, Wave Life Sciences, Hengrui Pharma, Novo, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Regeneron Ph3 Olatorepatide Obesity Study; Senseonics FIH Freedom Study; Corxel Goes Public; Awiqli Pediatric FDA Approval

A series of cardiometabolic-related news items has been observed from Regeneron, Senseonics, Corxel, and Novo/FDA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Potential New Brand Name for Cagrisema?; New Novo T2DM Asset; Zenagamtide Ph3 AMBITION 4 Registered; Tidepool Receives Grant Next-gen Algorithm

A series of cardiometabolic-related news items has been observed from Novo and Tidepool. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Roche Q3 ’26 Earnings; Rezera Files for IPO; Fractyl Restructuring; BI Partners with Microsoft; Lilly Ph2 oral GGG Obesity Study; AbbVie Lutikizumab Data and ABBV-295 Combination

A series of cardiometabolic-related news items has been observed from Roche, Rezera, Fractyl Health, Boehringer Ingelheim/Microsoft, Lilly, and AbbVie. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Publishes TRIUMPH-1 and TRIUMPH-2 OSA Results; Abbott Q3 ’26 Earnings; Novo Wegovy Pill France Launch; ADA CSO/CMO Transition

A series of cardiometabolic-related news items has been observed from Lilly, Abbott, Novo, and ADA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo REDEFINE 1 Post Hoc Analyses; Ascletis Preclinical QW Oral Peptide Data; Pfizer Berobenatide OSA Study; AZ/Oracle AI Partnership; Lilly/METiS LNP-Delivery Technology Partnership

A series of cardiometabolic-related news items has been observed from Novo, Ascletis Pharma, Pfizer, AstraZeneca/Oracle, and Lilly/METiS TechBio. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Merck Acquires Silence; Sanofi Insulin Manufacturing Expansion; Lilly Ph3 EloraTZP Pivotal Studies; Cytokinetics Myqorzo Health Canada Approval

A series of cardiometabolic-related news items has been observed from Merck KGaA, Sanofi, Lilly, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

October CHMP Agenda Highlights; Pfizer Initiates Q3M Berobenatide Study; Novo Licenses New Drug Discovery Platform; Fractyl Shares 6-Month Revita Procedure Results; FDA Reaffirms Reta’s Classificaiton as a Drug; MiniMed Appoints Board; Sequel twiist AID Insulin-Treated T2DM FDA Clearance

A series of cardiometabolic-related news items has been observed from EMA, Pfizer, Novo/Ablexis, Fractyl Health, FDA/Lilly, MiniMed, and Sequel Med Tech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novartis Terminates Ph3 Pelacarsen Studies; AZ Partners with insitro; Dexcom Publishes CONNECT RCT Results; Pfizer China-Based QM Berobenatide Obesity Study; Modular Medical Digital Learning Tool; Medtronic Finalizes MiniMed Separation; Atrogi Oral GRK2-Biased ß2-Adrenergic Modulator Data

A series of cardiometabolic-related news items has been observed from Novartis, AstraZeneca, Dexcom, Pfizer, Modular Medical, MiniMed, and Atrogi AB. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here